Sovenyr Get early access

Signal2026-07-03

EPO Patents

[EPO] COMBINED THERAPIES USING IMMUNOMODULATING DRUGS

Part of

Phase 2 Clinical Trial Developments

Open primary source See the whole picture

Powered by Sovenyr — cross-source signal intelligence. Figures are collected data as-dated, not investment advice.